Published in Hepatology on July 01, 2010
Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut (2011) 1.56
STAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver. J Hepatol (2012) 1.15
Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoimmunology (2012) 1.08
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med Mol Morphol (2011) 0.97
Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Mol Cancer Ther (2011) 0.96
Direct-acting antiviral medications for chronic hepatitis C virus infection. Gastroenterol Hepatol (N Y) (2011) 0.96
Xmrk, kras and myc transgenic zebrafish liver cancer models share molecular signatures with subsets of human hepatocellular carcinoma. PLoS One (2014) 0.93
Hepatocellular carcinoma: Where there is unmet need. Mol Oncol (2015) 0.93
Hepatoprotective versus oncogenic functions of STAT3 in liver tumorigenesis. Am J Pathol (2011) 0.91
Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology (2016) 0.91
YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma. Mol Cancer (2014) 0.90
Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. World J Gastroenterol (2015) 0.86
Anti-tumor Efficiency of Lipid-coated Cisplatin Nanoparticles Co-loaded with MicroRNA-375. Theranostics (2016) 0.85
Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. World J Gastroenterol (2014) 0.84
The combination of sorafenib and radiation preferentially inhibits breast cancer stem cells by suppressing HIF-1α expression. Oncol Rep (2013) 0.84
Diphenyl difluoroketone: a potent chemotherapy candidate for human hepatocellular carcinoma. PLoS One (2011) 0.83
Targeted therapy in hepatocellular carcinoma. Int J Hepatol (2011) 0.82
Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. J Transl Med (2014) 0.81
HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3. Oncotarget (2016) 0.81
Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Early Response to 4 Weeks of Treatment. Liver Cancer (2015) 0.81
Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes. Int J Nanomedicine (2015) 0.79
A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma. Integr Cancer Ther (2013) 0.77
Oncomirs miRNA-221/222 and Tumor Suppressors miRNA-199a/195 Are Crucial miRNAs in Liver Cancer: A Systematic Analysis. Dig Dis Sci (2016) 0.77
Fucoidan Elevates MicroRNA-29b to Regulate DNMT3B-MTSS1 Axis and Inhibit EMT in Human Hepatocellular Carcinoma Cells. Mar Drugs (2015) 0.77
GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo. Oncoimmunology (2015) 0.76
Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma. Onco Targets Ther (2016) 0.76
Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma. Oncotarget (2016) 0.75
Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery. Sci Rep (2016) 0.75
Comment on "combination treatment including targeted therapy for advanced hepatocellular carcinoma". Hepatobiliary Surg Nutr (2016) 0.75
Sorafenib with ASC-J9(®) synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals. Int J Cancer (2016) 0.75
Downregulation of ANP32B exerts anti-apoptotic effects in hepatocellular carcinoma. PLoS One (2017) 0.75
Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives. J Clin Transl Hepatol (2017) 0.75
Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals. Cell Death Dis (2017) 0.75
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med (2009) 22.23
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med (1999) 17.03
Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med (2008) 11.86
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med (2009) 11.63
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Global cancer statistics in the year 2000. Lancet Oncol (2001) 11.11
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol (2007) 11.04
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
Systemic therapy for colorectal cancer. N Engl J Med (2005) 8.94
Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet (2002) 7.67
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 6.13
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol (2008) 5.56
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol (2008) 3.32
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol (2007) 3.26
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol (2008) 3.00
Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol (2007) 2.69
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol (2009) 2.69
New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol (2008) 2.65
A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell (2009) 2.64
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol (2005) 2.56
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol (2009) 2.53
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 2.38
Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist (2009) 2.23
Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer (2009) 2.19
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol (2009) 2.16
Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology (2005) 1.90
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer (2007) 1.83
Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res (2005) 1.83
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol (2009) 1.75
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol (2008) 1.74
Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology (2004) 1.71
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol (2007) 1.66
Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology (2006) 1.64
Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res (2007) 1.57
Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res (2008) 1.57
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer (2007) 1.56
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther (2009) 1.54
Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer (2007) 1.51
Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol (2003) 1.45
The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res (2004) 1.42
Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol (2008) 1.41
Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol (2008) 1.37
Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression. Hepatology (2005) 1.30
Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med (2009) 1.30
Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol (2007) 1.29
Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer (2008) 1.25
Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol (2006) 1.21
RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med (2008) 1.19
Molecular profiling to predict hepatocellular carcinoma outcome. Expert Rev Gastroenterol Hepatol (2009) 1.17
Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. Dig Liver Dis (2003) 1.14
Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines. Gastroenterology (2009) 1.14
De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation (2007) 1.11
Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc (2008) 1.03
Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology (1998) 1.01
Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma. Cancer Lett (2005) 1.00
Effect of low-dose rapamycin on tumor growth in two human hepatocellular cancer cell lines. Transplant Proc (2009) 0.95
C-erb-B-2 oncoprotein and epidermal growth factor receptor in human hepatocellular carcinoma: an immunohistochemical study. Histol Histopathol (1994) 0.92
Lymphotoxins: new targets for hepatocellular carcinoma. Cancer Cell (2009) 0.83
Sirolimus therapy in liver transplant patients: an initial experience at a single center. Transplant Proc (2008) 0.81
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Burden of liver disease in the United States: summary of a workshop. Hepatology (2002) 4.00
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology (2007) 3.57
Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology (2007) 3.40
Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology (2014) 3.29
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
Clinical practice. Microscopic hematuria. N Engl J Med (2003) 2.96
Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg (2009) 2.95
A population-based cohort study comparing laparoscopic cholecystectomy and open cholecystectomy. Am J Gastroenterol (2002) 2.75
Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology (2007) 2.72
Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol (2007) 2.69
Clinical risk factors for portopulmonary hypertension. Hepatology (2008) 2.62
Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol (2002) 2.55
Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection. J Infect Dis (2009) 2.53
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40
Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology (2003) 2.38
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology (2014) 2.28
Steroid use in acute liver failure. Hepatology (2013) 2.23
Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol (2004) 2.12
Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. Hepatology (2011) 2.01
Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg (2004) 1.79
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology (2011) 1.63
Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease. Gastroenterology (2010) 1.60
Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2011) 1.59
Hepatitis C virus and liver transplantation. Clin Liver Dis (2006) 1.58
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58
Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl (2003) 1.57
Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology (2007) 1.56
Health-related quality of life and survival in liver transplant candidates. Liver Transpl (2010) 1.55
Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C. Liver Transpl (2012) 1.54
Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. Liver Transpl (2013) 1.52
Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology (2008) 1.50
Prevalence of HBV precore/core promoter variants in the United States. Hepatology (2003) 1.47
Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med (2009) 1.44
Fistula first is not always the best strategy for the elderly. J Am Soc Nephrol (2013) 1.30
Living donor liver transplantation: summary of a conference at The National Institutes of Health. Liver Transpl (2002) 1.22
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology (2013) 1.21
Summary report of a national conference: Evolving concepts in liver allocation in the MELD and PELD era. December 8, 2003, Washington, DC, USA. Liver Transpl (2004) 1.19
Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol (2010) 1.17
The survival impact of liver transplantation in the MELD era, and the future for organ allocation and distribution. Am J Transplant (2005) 1.16
Hospitalization rates before and after adult-to-adult living donor or deceased donor liver transplantation. Ann Surg (2010) 1.13
Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci (2012) 1.12
Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma. Cancer (2010) 1.12
Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol (2010) 1.10
Point-of-care photomicroscopy of urine. N Engl J Med (2011) 1.09
Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology (2011) 1.09
Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. Am J Gastroenterol (2009) 1.06
Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol (2011) 1.06
Diabetes, body mass index, and outcomes in hepatocellular carcinoma patients undergoing liver transplantation. Transplantation (2012) 1.03
Chronic hepatitis C virus and celiac disease, is there an association? Dig Dis Sci (2007) 1.03
Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol (2007) 1.03
Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol (2003) 1.02
Hypothermic machine preservation attenuates ischemia/reperfusion markers after liver transplantation: preliminary results. J Surg Res (2010) 1.02
A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol (2005) 1.02
One-year morbidity after donor right hepatectomy. Liver Transpl (2004) 1.01
Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality. Am J Gastroenterol (2003) 0.95
Analysis of failure in living donor liver transplantation: differential outcomes in children and adults. World J Surg (2003) 0.95
Impact of adult living donor liver transplantation on waiting time survival in candidates listed for liver transplantation. Am J Transplant (2004) 0.95
Adult living donor liver transplantation. Am J Transplant (2004) 0.91
Polysomy and p16 deletion by fluorescence in situ hybridization in the diagnosis of indeterminate biliary strictures. Gastrointest Endosc (2011) 0.91
Cotton plants expressing a hemipteran-active Bacillus thuringiensis crystal protein impact the development and survival of Lygus hesperus (Hemiptera: Miridae) nymphs. J Econ Entomol (2012) 0.90
Transplantation for alcoholic hepatitis--time to rethink the 6-month "rule". N Engl J Med (2011) 0.89
Predictors of mortality and stenosis after transjugular intrahepatic portosystemic shunt. Liver Transpl (2002) 0.89
Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C. Gastroenterology (2009) 0.89
Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl (2006) 0.88
Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl (2012) 0.88
Discovery of diffuse biliary microhamartomas during liver procurement. Liver Transpl (2007) 0.88
Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation (2015) 0.88
Has the time come to include urine dipstick testing in screening asymptomatic young adults? JAMA (2011) 0.87
Evaluation of living liver donors. Prog Transplant (2003) 0.87
Factors predicting failure of AV "fistula first" policy in the elderly. Hemodial Int (2013) 0.87
Clinical and ethnic differences in candidates listed for liver transplantation with and without potential living donors. Liver Transpl (2003) 0.87
Predictors of candidate maturation among potential living donors. Am J Transplant (2005) 0.87
Hepatitis C and liver transplantation: enhancing outcomes and should patients be retransplanted. Clin Liver Dis (2008) 0.86
Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C: results from the WIN-R trial. J Clin Gastroenterol (2011) 0.86
Obesity and microvascular invasion in hepatocellular carcinoma. Cancer Invest (2010) 0.85
Hepatitis C genotype influences post-liver transplant outcomes. Transplantation (2015) 0.85
Mycophenolate mofetil for drug-induced vanishing bile duct syndrome. World J Gastroenterol (2007) 0.85
Successful sequential liver and stem cell transplantation for hepatic failure due to primary AL amyloidosis. Gastroenterology (2002) 0.85
Disparities in arteriovenous fistula placement in older hemodialysis patients. Hemodial Int (2013) 0.85
Liver and intestine transplantation. Am J Transplant (2003) 0.83
Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients. Oncology (2014) 0.83
Serotonin transporter polymorphisms in patients with portopulmonary hypertension. Chest (2009) 0.83
Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience. Transplantation (2013) 0.83
Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy. J Clin Gastroenterol (2004) 0.83
Effects of ethnicity and socioeconomic status on survival and severity of fibrosis in liver transplant recipients with hepatitis C virus. Liver Transpl (2012) 0.83
Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation. Liver Transpl (2014) 0.82
Kidney and liver living donors: a comparison of experiences. Prog Transplant (2005) 0.82
Interpretation of liver chemistries in adult donors after living donor liver transplantation. J Clin Gastroenterol (2004) 0.82
The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) program in practice: does it really inform patients and limit risk? Am J Kidney Dis (2012) 0.82
Characterization of the active site and insight into the binding mode of the anti-angiogenesis agent fumagillin to the manganese(II)-loaded methionyl aminopeptidase from Escherichia coli. J Biol Inorg Chem (2004) 0.82
Who should treat liver transplant patients? The transplant hepatologist or the gastroenterologist? Part I: the transplant hepatologist. J Hepatol (2006) 0.82
Live donor liver transplantation: current status. Curr Gastroenterol Rep (2008) 0.82
Prevention of post-transplant cardiovascular disease--report and recommendations of an ad hoc group. Am J Transplant (2002) 0.81
Smoking and hepatocellular carcinoma mortality. Exp Ther Med (2011) 0.81
The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV. Am J Gastroenterol (2005) 0.81
Use of Complementary and Alternative Medicine among Patients with End-Stage Renal Disease. Evid Based Complement Alternat Med (2013) 0.81